ROCKET PHARMACEUTICALS, INC.

During the six months ended June 30, 2025, operating activities used $104.8 million of cash and cash equivalents, primarily resulting from our net loss of $130.3 million offset by net non-cash charges of $22.5 million, including non-cash stock-based compensation expense of $21.2 million, depreciation and amortization expense of $5.6 million, partially offset by accretion of discount on investments of $4.3 million. Changes in our operating assets and liabilities for the six months ended June 30, 2025, included a decrease in accounts payable and accrued expenses of $2.9 million and an increase in our prepaid expenses of $0.2 million.

During the six months ended June 30, 2024, operating activities used $110.7 million of cash and cash equivalents, primarily resulting from our net loss of $131.7 million offset by net non-cash charges of $19.4 million, including non-cash stock-based compensation expense of $21.6 million, depreciation and amortization expense of $4.6 million, partially offset by accretion of discount on investments of $5.0 million and reduction in fair value of warrant liabilities of $1.8 million. Changes in our operating assets and liabilities for the six months ended June 30, 2024, included a decrease in accounts payable and accrued expenses of $2.1 million, and increase in our prepaid expenses of $0.7 million.